Skip to content
Infuvite adult, Fosavance(cholecalciferol)
Adrovance, Fosamax D, Fosavance, Infuvite, Vantavo (cholecalciferol) is a small molecule pharmaceutical. Cholecalciferol was first approved as Infuvite adult on 2000-05-18. It is used to treat cardiovascular diseases, chronic kidney failure, crohn disease, familial hypophosphatemic rickets, and hypoparathyroidism amongst others in the USA. It has been approved in Europe to treat postmenopausal osteoporosis.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
musculoskeletal diseasesD009140
digestive system diseasesD004066
respiratory tract diseasesD012140
urogenital diseasesD000091642
cardiovascular diseasesD002318
hereditary congenital and neonatal diseases and abnormalitiesD009358
skin and connective tissue diseasesD017437
nutritional and metabolic diseasesD009750
endocrine system diseasesD004700
Show 1 more
Trade Name
FDA
EMA
Combinations
Fosamax d, Infuvite
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Alendronate sodium
+
Cholecalciferol
Tradename
Company
Number
Date
Products
FOSAMAX PLUS DOrganonN-021762 RX2005-04-07
2 products, RLD
Alpha-tocopherol acetate
+
Ascorbic acid
+
Biotin
+
Cholecalciferol
+
Cyanocobalamin
+
Dexpanthenol
+
Folic acid
+
Niacinamide
+
Pyridoxine hydrochloride
+
Riboflavin 5'-phosphate sodium
+
Thiamine hydrochloride
+
Vitamin a palmitate
+
Vitamin k
Tradename
Company
Number
Date
Products
INFUVITE ADULTSandozN-021163 RX2000-05-18
2 products, RLD, RS
Ascorbic acid
+
Biotin
+
Cholecalciferol
+
Cyanocobalamin
+
Dexpanthenol
+
Folic acid
+
Niacinamide
+
Pyridoxine
+
Riboflavin
+
Thiamine
+
Tocopherol acetate
+
Vitamin a
+
Vitamin k
Tradename
Company
Number
Date
Products
INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE)SandozN-021265 RX2004-01-29
1 products, RLD, RS
INFUVITE PEDIATRICSandozN-021265 RX2001-02-21
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
adult infuvite multiple vitaminsNew Drug Application2016-10-28
fosamax plus dNew Drug Application2021-08-31
growth supportpatch, hautukiunapproved drug other2023-05-22
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
cardiovascular diseasesEFO_0000319D002318I98
chronic kidney failureEFO_0003884D007676N18.6
crohn diseaseEFO_0000384D003424K50
familial hypophosphatemic ricketsD053098
hypoparathyroidismD007011E20
lung neoplasmsD008175C34.90
osteoporosisEFO_0003882D010024M81.0
psoriasisEFO_0000676D011565L40
skin neoplasmsEFO_0004198D012878C44
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
A11: Vitamins
A11C: Vitamin a and d, incl. combinations of the two
A11CC: Vitamin d and analogues
A11CC05: Colecalciferol
A11CC55: Colecalciferol, combinations
M: Musculo-skeletal system drugs
M05: Drugs for treatment of bone diseases
M05B: Drugs affecting bone structure and mineralization
M05BB: Bisphosphonates, combinations affecting bone structure and mineralization
M05BB03: Alendronic acid and colecalciferol
M05BB04: Risedronic acid, calcium and colecalciferol, sequential
M05BB05: Alendronic acid, calcium and colecalciferol, sequential
M05BB07: Risedronic acid and colecalciferol
M05BB08: Zoledronic acid, calcium and colecalciferol, sequential
M05BB09: Ibandronic acid and colecalciferol
M05BX: Other drugs affecting bone structure and mineralization in atc
M05BX53: Strontium ranelate and colecalciferol
HCPCS
No data
Clinical
Clinical Trials
1668 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Vitamin d deficiencyD014808EFO_0003762E5537614569240432
OsteoporosisD010024EFO_0003882M81.0918282127101
Covid-19D000086382U07.1361153458
ObesityD009765EFO_0001073E66.925392948
Type 2 diabetes mellitusD003924EFO_0001360E11311691742
Healthy volunteers/patients72322336
AsthmaD001249EFO_0000270J4549841134
Chronic renal insufficiencyD051436N18246101434
Metabolic bone diseasesD001851HP_000093835491433
Postmenopausal osteoporosisD015663EFO_00038544613730
Show 130 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Breast neoplasmsD001943EFO_0003869C5081910436
Prostatic neoplasmsD011471C612126322
Inflammatory bowel diseasesD015212EFO_0003767322814
Hiv infectionsD015658EFO_0000764B2094213
TuberculosisD014376EFO_0000774A15-A1942713
Colorectal neoplasmsD015179162612
PregnancyD011247EFO_0002950Z33.1113611
NeoplasmsD009369C80315210
AgingD000375GO_0007568R41.81111810
Spinal cord injuriesD013119EFO_1001919153410
Show 92 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HyperparathyroidismD006961EFO_0008506E21.31146
Bone densityD015519EFO_0003923M85145
Stress fracturesD015775M84.3145
AtherosclerosisD050197EFO_0003914I25.1145
Pre-eclampsiaD011225EFO_0000668O141145
Rectal neoplasmsD0120041124
Ovarian neoplasmsD010051EFO_0003893C561214
Female infertilityD007247EFO_0008560N97134
Hematopoietic stem cell transplantationD0183801134
Severe acute respiratory syndrome-related coronavirusD045473NCBITaxon_227859123
Show 70 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Nutritional statusD009752134
PeriodontitisD010518EFO_0000649K05.3134
Periodontal diseasesD010510K05.6134
Tibial fracturesD013978EFO_0003944S82.20112
Morbid obesityD009767EFO_0001074112
Thyroid diseasesD013959HP_0000820E00-E07112
GrowthD006128112
Breast densityD00007106011
Chronic progressive multiple sclerosisD02052811
Pituitary acth hypersecretionD047748EFO_1001110E24.011
Show 14 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Pregnancy complicationsD01124833
Wounds and injuriesD014947T14.833
Renal dialysisD006435EFO_0010690Z99.233
Weight lossD015431HP_000182433
HeadacheD006261HP_0002315R5122
Allergic rhinitisD065631J30.922
Vitamin k deficiencyD014813E56.122
Fracture healingD01710222
Female genital diseasesD005831EFO_0009549N8522
HypercholesterolemiaD006937HP_000312422
Show 140 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCHOLECALCIFEROL
INNcolecalciferol
Description
Fosamax Plus D (cholecalciferol) is a small molecule pharmaceutical. Cholecalciferol was first approved as Fosamax plus d on 2005-04-07. It is used to treat cardiovascular diseases, chronic kidney failure, crohn disease, familial hypophosphatemic rickets, and hypoparathyroidism amongst others in the USA.
Classification
Small molecule
Drug classvitamin D analogs
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)C
Identifiers
PDB
CAS-ID67-97-0
RxCUI2418
ChEMBL IDCHEMBL1042
ChEBI ID28940
PubChem CID5280795
DrugBankDB00169
UNII ID1C6V77QF41 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 13,449 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
61,060 adverse events reported
View more details